EcoDrugPlus

Proto-Oncogene Tyrosine-Protein Kinase Src-Like

Ensembl ID : ENSOKIG00005019926
Gene Symbol: LOC109869522
3 Cross references
191 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret

Ensembl ID : ENSOKIG00005003733
Gene Symbol: LOC109889771
3 Cross references
199 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret-Like

Ensembl ID : ENSOKIG00005021999
Gene Symbol: LOC109899062
3 Cross references
199 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSOKIG00005017168
Gene Symbol: P2RY1
3 Cross references
185 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSOKIG00005039141
Gene Symbol: P2RY1
3 Cross references
184 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSOKIG00005008846
Gene Symbol: P2RY2
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSOKIG00005017503
Gene Symbol: P2RY2
3 Cross references
191 Possible Orthologues:

Putative Transcription Factor P65 Homolog

Ensembl ID : ENSOKIG00005010910
Gene Symbol: LOC109897090
3 Cross references
194 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSOKIG00005014778
Gene Symbol: P2RY4
3 Cross references
159 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSOKIG00005017620
Gene Symbol: P2RY4
3 Cross references
160 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSOKIG00005017626
Gene Symbol: P2RY6
3 Cross references
176 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSOKIG00005008672
Gene Symbol: P2RY6
1 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).